Longeveron Announces Engagement of Lucid Capital Markets
Longeveron Inc LGVN
$2.84
▲ +41.29%
(+$0.83)
⬆️ Above Yest. High
🎈 Low Float
📅 Earnings This Week
Open
$2.08
Prev Close
$2.01
Day Range
$1.98 – $2.86
52W Range
$1.31 – $12.30
Market Cap
$6.41M
Beta
1.02
EPS (TTM)
$-6.72
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-12 |
| Shares Out. | 3,190,000 |
| Website | longeveron.com/ ↗ |
| Phone | 13026744089 |
| Employees | 38 |
| Revenue | $287,000 |
| Gross Profit | $182,000 |
| Net Income | -$6.1M |
| Free Cash Flow | -$20.5M |
| Total Assets | $15.5M |
| Total Liabilities | $5.1M |
| Equity | $10.4M |
About Longeveron Inc
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Longeveron Inc is a publicly traded company under the ticker symbol LGVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-11-01)